PharmaCyte Biotech, Inc. (PMCB)
USD 1.2
(-2.44%)
USD 1.2
(-2.44%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.15 Million | -3.79 Million | -4.11 Million | -3.33 Million | -2.33 Million | -2.87 Million |
| Net Income | 333.76 Thousand | -4.31 Million | -4.23 Million | -3.55 Million | -3.82 Million | -4.06 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 674.69 Thousand | 645.4 Thousand | 77.95 Thousand | 370.82 Thousand | 748.02 Thousand | 705.67 Thousand |
| Change in working capital | 298.89 Thousand | -297.16 Thousand | 9040.00 | -145.6 Thousand | 267.34 Thousand | 167.09 Thousand |
| Other non-cash items | -3.04 Million | 174.02 Thousand | 34.84 Thousand | -4874.00 | 473.14 Thousand | 316.53 Thousand |
| Investing Cash Flow | -5 Million | - | - | - | - | - |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -5 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -5 Million | - | - | - | - | - |
| Financing Cash Flow | -10.7 Million | -13.55 Million | 87.31 Million | 4.63 Million | 2.72 Million | 2.34 Million |
| Debt repayment | - | - | -50.8 Thousand | -62.44 Thousand | -12.35 Thousand | - |
| Dividends payments | -22.45 Million | - | - | - | - | - |
| Common Stock Repurchased | -28.19 Million | -13.56 Million | - | - | -1.00 | - |
| Common Stock Issuance | 33.65 Million | 880.00 | 87.36 Million | 4.69 Million | 2.66 Million | 2.34 Million |
| Other Financing Activities | 6.29 Million | -13.55 Thousand | -50.8 Thousand | -62.44 Thousand | 75.2 Thousand | 2342.50 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 261.09 Thousand | -242.94 Thousand | 33.1 Thousand | -13.58 Thousand | 63.95 Thousand | -230.73 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 37.8 Thousand | 242.94 Thousand | -24.06 Thousand | -132.02 Thousand | 203.39 Thousand | 397.83 Thousand |
| Cash at beginning of period | 68.03 Million | 85.4 Million | 2.2 Million | 894.86 Thousand | 515.25 Thousand | 1.05 Million |
| Cash at end of period | 50.17 Million | 68.03 Million | 85.4 Million | 2.2 Million | 894.86 Thousand | 515.25 Thousand |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | -508.00 | -7246.00 | 4625.00 | 1327.00 | -7867.00 | -9133.00 |
| Net cash flow / Change in cash | -17.85 Million | -17.36 Million | 83.19 Million | 1.3 Million | 379.6 Thousand | -544.54 Thousand |
| Free Cash Flow | -2.15 Million | -3.79 Million | -4.11 Million | -3.33 Million | -2.33 Million | -2.87 Million |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 333.76 Thousand | 1.34 Million | -619.53 Thousand | 2.78 Million | -3.18 Million | -4.31 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 674.69 Thousand | 674.69 Billion | 674.69 Thousand | - | - | 645.4 Thousand |
| Change in working capital | 298.89 Thousand | 87.14 Thousand | 135.74 Thousand | -554.61 Thousand | 630.61 Thousand | -297.16 Thousand |
| Other non-cash items | -3.04 Million | -1.67 Million | -368 Thousand | -4.21 Million | 2.89 Million | 174.02 Thousand |
| Investing Cash Flow | -5 Million | -4999.99 Billion | -5 Million | -643.24 Thousand | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -5 Million | 5 Million | -5 Million | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -5 Million | -4999.99 Billion | -5000.00 | - | - | - |
| Financing Cash Flow | -10.7 Million | -10.69 Million | -7.03 Million | 748.68 Thousand | 6.27 Million | -13.55 Million |
| Debt repayment | - | -319.91 Thousand | - | - | -319.91 Thousand | - |
| Dividends payments | -22.45 Million | -22457.22 Billion | - | - | -319.84 Thousand | - |
| Common Stock Repurchased | -28.19 Million | -10.69 Million | -7.03 Million | -164.95 Thousand | -26.45 Million | -13.56 Million |
| Common Stock Issuance | 33.65 Million | 33650.03 Billion | - | 913.64 Thousand | 35 Million | 880.00 |
| Other Financing Activities | 6.29 Million | 6296.76 Billion | -6638.20 | 913.64 | -1.62 Million | -13.55 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 261.09 Thousand | -94.82 Thousand | 358.03 Thousand | -591.96 Thousand | 589.84 Thousand | -242.94 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 37.8 Thousand | 181.97 Thousand | -222.29 Thousand | 37.35 Thousand | -589.84 Thousand | 242.94 Thousand |
| Cash at beginning of period | 68.03 Million | 61.21 Million | 73.42 Million | 74.66 Million | 68.03 Million | 85.4 Million |
| Cash at end of period | 50.17 Million | 50.17 Million | 61.21 Million | 73.42 Million | 74.66 Million | 68.03 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -508.00 | -438.00 | 1070.00 | -1591.00 | 451.00 | -7246.00 |
| Net cash flow / Change in cash | -17.85 Million | -11.03 Million | -12.21 Million | -1.23 Million | 6.62 Million | -17.36 Million |
| Free Cash Flow | -2.15 Million | -332.95 Thousand | -177.1 Thousand | -1.98 Million | 342.95 Thousand | -3.79 Million |
7389
1579
FQVLF
TMG
2667
CTLP